{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '10.', 'STUDY TREATMENTS', '10.1.', 'Treatments Administered', '10.1.1.', 'Study Treatments', 'Selinexor will be provided as film-coated, immediate-release tablets for oral administration in', 'blister packs. Selinexor tablets will contain selinexor 20 mg of the Active Pharmaceutical', 'Ingredient (API). Refer to the Study Manual for selinexor storage.', 'Bortezomib (for SC injection) and dexamethasone (oral tablets) to be used in combination with', 'selinexor in this study will be obtained by the investigational sites, unless otherwise specified in', 'the contractual agreement. Bortezomib and dexamethasone should be stored as described on their', 'respective product labels.', 'Study treatments must be dispensed only by a pharmacist or appropriately qualified staff. Study', 'treatments are to be dispensed only to patients enrolled in this study.', '10.2.', 'Dose Schedules and Administration', '10.2.1.', 'Labeling', 'All labels will include conditions for storage, lot number, and other information required by the', 'Food and Drug Administration (FDA), International Council for Harmonisation (ICH), and/or', 'Annex 13, and all local regulations for investigational medications.', '10.2.2.', 'Dispensing Directions', 'Dispensing instructions for selinexor will be provided in the Study Manual.', '10.2.3.', 'Dosing Information', '10.2.3.1. Dosing Sequence and Timing', 'In general, where possible, each study treatment (ie, selinexor, bortezomib, dexamethasone)', 'should be given at least 1 to 2 hours apart. However, on C2D15 (the day of PK sampling for', 'patients in the PK subset of the SVd Arm), selinexor should be dosed within 15 minutes prior to', 'bortezomib (Section 11.4).', 'Dexamethasone should be administered at least 1 hour before selinexor (SVd Arm) and', 'bortezomib.', '10.2.3.2. Selinexor', 'For details of selinexor formulation, preparation, and administration, please refer to the Study', 'Manual.', 'Selinexor tablets should be taken orally with at least 120 mL (4 ounces) of water at', 'approximately the same time each day. It can be taken with or without food. Selinexor tablets', 'should be swallowed whole (not crushed) to prevent an increased risk of dermatologic toxicity if', 'the powder comes in contact with skin.', 'Confidential', 'Page 59', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'For doses of selinexor that are to be taken on non-clinic days, the patient will be provided with', 'selinexor by the site pharmacy and selinexor may be self-administered by the patient on an', 'outpatient basis.', '10.2.3.3. Bortezomib', 'For details of bortezomib formulation, preparation, and administration, please refer to the full', 'prescribing information for bortezomib (different local/regional trade names may be used).', 'Bortezomib will only be administered by qualified site personnel during clinic visits in', 'accordance with the prescribing information for bortezomib (in the appropriate local language).', '10.2.3.4. Dexamethasone', 'For details of dexamethasone formulation, preparation, and administration, please refer to the', 'full prescribing information for dexamethasone as it is locally available.', 'For doses of dexamethasone that are to be taken on non-clinic days, the patient will be provided', 'with dexamethasone and its schedule of administration by the site pharmacy. Dexamethasone', 'may be self-administered by the patient on an outpatient basis.', '10.2.4.', 'Dose Schedules for Evaluation', 'See Section 10.4 for dose modifications.', '10.2.4.1. SVd Arm', 'The dose schedule for the SVd Arm (5-week [35-day] cycle) is provided in Table 8.', 'Selinexor will be given as a fixed oral 100 mg dose on Days 1, 8, 15, 22, and 29 of', 'each 35-day cycle.', 'Bortezomib will be given at a dose of 1.3 mg/m\u00b2 SC on Days 1, 8, 15, and 22 of each', '35-day cycle.', 'Dexamethasone will be given as an oral 20 mg dose on Days 1, 2, 8, 9, 15, 16, 22, 23,', '29, and 30 of each 35-day cycle.', 'In no case may the selinexor dose exceed 70 mg/m\u00b2 per dose for any patient (see', 'Section 11.5.1.1).', '10.2.4.2. Vd Arm', 'The dose schedule for Cycles 1 through 8 (3-week [21-day] cycle) for the Vd Arm is provided', 'in Table 9.', 'Bortezomib will be given at a dose of 1.3 mg/m\u00b2 SC on Days 1, 4, 8, and 11 of each', '21-day cycle for the first 8 cycles.', 'Dexamethasone will be given as an oral 20-mg dose on Days 1, 2, 4, 5, 8, 9, 11, and', '12 of each 21-day cycle for the first 8 cycles.', 'The dose schedule for Cycles >9 (5-week [35-day] cycle) for the Vd Arm is provided in', 'Table 10.', 'Confidential', 'Page 60', 'Version 4.0']\n\n###\n\n", "completion": "END"}